Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Menactra®
Meningococcal Diphtheria Toxoid Vaccine · 1 trial · 2 indications
Functional antibody activity against the meningococcal serogroups A, C, Y, and W-135 antigens contained in Menactra vaccine was measured using a SBA-HC assay. Seroprotection was defined as antibody titers ≥ 1:8.
| Arm | Type | Description |
|---|---|---|
| Meningococcal Diphtheria Toxoid Vaccine | EXPERIMENTAL | Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart |
| Name | Type | Description |
|---|---|---|
| Meningococcal Diphtheria Toxoid Vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Male and female subjects aged 9 to 17 months on the day of inclusion * Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative(s) (if applicable) * Subject and parent/legally acceptable representative (if applicable) able to ...
The Meningococcal Diphtheria Toxoid Vaccine is used to prevent meningococcal infection and meningitis. It is a vaccine developed by Sanofi that stimulates an immune response against meningococcal disease. The vaccine is intended for use in young children, with clinical testing conducted in subjects aged 9 to 23 months.
The Meningococcal Diphtheria Toxoid Vaccine is developed by Sanofi, which trades under the ticker SNY. Sanofi conducted the clinical development of this vaccine candidate for the prevention of meningococcal infection and meningitis.
The Meningococcal Diphtheria Toxoid Vaccine is in Phase 3 clinical development. One Phase 3 trial has been completed. The vaccine is investigational and has not been approved by the FDA based on the available information.
The Meningococcal Diphtheria Toxoid Vaccine has been evaluated in one Phase 3 clinical trial, NCT01890759, titled Immunogenicity and Safety of Menactra Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation. The trial enrolled 300 participants, was conducted in India and Russia, and has been completed.
The Meningococcal Diphtheria Toxoid Vaccine targets meningococcal bacteria to prevent meningitis and meningococcal infection. It is a vaccine that uses diphtheria toxoid as a carrier protein to elicit an immune response against meningococcal disease.